The second round of volume procurement fire has been burned to self-cost medicine

the "4 plus 7" belt procurement and subsequent expansion, 25 pilot varieties are all for the national health insurance catalogue drugs. And the second round of volume procurement of 35 varieties, there have been a number of non-national health insurance catalog drugs. In addition to the expansion of the belt procurement, in the provinces and cities every flowering, its policy objectives are becoming more prominent, not only through volume-for-price reduction of the burden of medical insurance funds, but also through volume procurement bidding to explore new mechanisms to reduce drug prices.
On December 6, 2019, just one year after the first "4 plus 7" volume procurement, the Joint Procurement Office announced that the second round of belt procurement officially entered the critical countdown by convening a symposium of more than 100 related enterprises, and that it would land bidding after half a month to two months, while 35 varieties of medical institutions previously circulating online were also recognized as the final varieties of the second volume procurement expansion.It is worth noting that the second round of belt procurement varieties not only in terms of quantity than the first round of band procurement varieties increased by 10, but also in the nature and structure of the varieties have changed a lot.Comparing the 2017 and 2019 editions of the National Health Insurance Catalog, it can be found that the first round of "4 plus 7" and subsequent expansion of the volume of procurement of 25 pilot varieties of drugs are all in the National Health Insurance Catalog, but the new round of procurement of 35 pilot varieties, there have been 5 not included in the 2017 National Health Insurance Catalog of self-cost drugs. This means that volume purchases, which were intended to reduce the pressure on national health-care funding through volume-for-price, are spreading beyond the national health-care directory after being included in the pilot of out-of-the-nation drugs.01 With volume procurement, knife price!An analysis was carried out of 35 pilot varieties purchased in the second round of belt volume, five of which were self-contained medicines not included in the national health insurance catalogue for 2017. Of these five varieties, Solana was included in the 2019 National Health Care General Directory adjustment, A capo sugar was eventually included in the 2019 National Health Insurance Directory through drug price negotiations, and the remaining three varieties, Adelfovester, Allison Tan and Tadarafei, were not included in the two versions of the National Health Insurance Directory.

And business-related people in an interview with E drug managers, said that the relevant person in charge of consulting the collection and collection, these self-funded drugs will not be because of participation in the second round of volume procurement and adjustment into the national health insurance directory.Of the five varieties, Solana was successfully added to the 2019 national health care routine in August after a series of expert assessments. Relevant information shows that through the consistent evaluation of the original drug has reached 4, after entering the second round of volume procurement, the relevant price competition is bound to be fierce.Acapo sugar is more serious than solana's new situation, while the national health care drug price negotiations and a new round of national procurement of the dual policy shock.In the new round of national health care negotiations, A capo sugar successfully entered the new version of the national health care directory. Although the price of Akapo sugar health insurance negotiations is still confidential, but on December 3, Yunnan Province's centralized drug procurement platform announced the recent changes in drug information on the Internet, Hangzhou Sino-American East China Pharmaceutical Co., Ltd. produced Akapo sugar chewing tablets (50mg) price changes, from 2.6877 yuan / tablet to 1.1 yuan / tablet, a decrease of 59.11%.Acapo glycogen research drug companies for Bayer, through generic drug consistency evaluation of domestic pharmaceutical companies only East China Medicine and Green Leaf Pharmaceutical two.Bayer accounts for 69% of Acapo sugar market share, 26% in east China and 5% in Sichuan's Green Leaf Baoguang Pharmaceuticals, according to the Minnet City Public Hospital Terminal Data. According to the annual report of listed companies, The sales revenue of East China Pharmaceutical Akapo sugar exceeded 1 billion yuan in 2015, 1.5 billion yuan in 2016 and 2 billion yuan in 2017.In the national health insurance price negotiations at the same time, A capo sugar into a new round of national volume procurement of 35 pilot varieties, indicating that the relevant policy layer for diabetes drug a capabo sugar has further price reduction expectations, a capo sugar is also facing greater pressure to reduce prices.02 With volume procurement to accelerate the arrival of the "patent cliff"!In addition to Acapo sugar and solana, Adelfovesters, tadalaf and Allison Tan are all self-cost drugs, meaning that the war on volume purchases has spread above the price of medicines outside the National Health Insurance Directory.Adelfovester is a drug for hepatitis B. According to Milnet data, the overall domestic market for anti-hepatitis B virus drugs in 2017 has reached 15 billion yuan in size, from the market share of various varieties, Enticave accounted for 67.25 percent, Adelfovir accounted for 11.97 percent, Ramifedin accounted for 9.36 percent, Tyvedin accounted for 6.47 percent, tenofovir diosteride accounted for 4.96 percent. Adelfovir has formed the original research and generic drug companies in the local "1 plus 2" pattern, the price fight between the companies will undoubtedly be very fierce.Hedalla is not an anti-ED drug. In the domestic market, due to the late entry of Tadara non-entry into China and not well-known, the main share of the anti-ED drug market is still occupied by foreign-funded original research drug Sidna non-generic drugs. In 2017, the overall market size of the anti-ED drug PDE5 inhibitors in China reached 2,994 million yuan, of which 2.23 billion yuan was in Xidana and 739 million yuan in Tadaraf.He Dalafei has not yet been included in the national health insurance directory, and is also available to buy in retail pharmacies over-the-counter drugs, its original research drug companies for Lilly, over-consistent evaluation of domestic generic drug companies have Qilu, Zhengda Tianqing and Changchun Haiyue three, four fierce price killing, whether it will also have an impact on retail pharmacies and other channels of drug prices, worthy of attention.And Anlisantan is used for pulmonary hypertension. Pulmonary hypertension drug Anlisantan tablet sales of nearly $1 billion a year, but because the original patents of GSK and Gilead have just expired and are expensive, according to Minenet data, Anlitan domestic public hospital sales of only 310,000 yuan.And domestic manufacturers in Anli Shengtan listed and through the consistency of evaluation of only two. On December 13, 2018, Jiangsu Hausen Anlitan was listed and evaluated as consistent. On May 9, 2019, Zhengda Qing An Lishengtan was listed and evaluated as consistent.Shortly after the listing of two domestic generic drugs, Anli Shengtan will enter the volume procurement, which is also in the hint that the volume of procurement is not only to the market for a long time expired original research drug species, some of the varieties just after the patent period may soon encounter the volume of procurement, China's "patent cliff" will be with the help of volume procurement to accelerate the arrival.03 Adjusting drug prices is also the core workIt is worth noting that, although the initial key policy intention of volume procurement is to reduce drug expenditure in the national health insurance catalogue and reduce the financial burden of national health insurance, but with the gradual maturity of the experience related to volume procurement, volume procurement is also becoming a new mechanism for regulating drug prices, and in the provinces and cities pilot flowering every place.In March last year, the dust settled on the "major reform" of state institutions, and the "one-in-four" National Health Insurance Administration came out of the sky. The newly established State Health Insurance Bureau merges the basic medical insurance and maternity insurance duties of urban workers and urban residents of the Ministry of People's Insurance; the new agricultural joint duties of the Ministry of Health and Planning; the medical assistance duties of the Ministry of Civil Affairs; the price management of medicines and medical services of the National Development and Reform Commission; the bidding and procurement duties of medicines and supplies; and the right to supervise the conduct and charges of medical services in the medical insurance category; and entrusts the responsibility for collecting medical insurance and maternity insurance expenses to the tax department.And the second round of volume procurement into self-funded drugs, meaning that the State Health Insurance Administration not only by means of volume procurement, reduce the unreasonable high price of drugs in the national health insurance catalogue, but also by the volume procurement to explore new ways of drug price management, in order to assume the past NDRC drug and medical services price management responsibilities.On November 29, 2019, the Leading Group of the State Council for Deepening the Reform of the Medical and Health System issued a notice on a number of policy measures to further deepen the reform of the medical and health system with the centralized procurement and use of medicines as a breakthrough, and also emphasized that Drug, all regions should rely on the provincial drug centralized procurement platform, learn from the experience of the centralized procurement and use of drugs organized by the state, take individual or cross-regional alliances and other ways, in the procurement of drug scope, shortlisting standards, centralized procurement forms and other aspects to increase reform and innovation efforts, forming a national and local mutual promotion of the work pattern.At the same time, the circular encourages the exploration of group procurement, joint procurement of specialized hospitals, procurement of medical complexes and other ways to form reasonable prices, while encouraging non-public medical institutions, social pharmacies and other active participation, and jointly promote the formation of market-oriented drug price formation mechanism.In fact, Hebei Province, Wuhan City, Guangxi Province and other places have responded to the call to try to use the method of volume procurement in the local drug bidding work, and in the pilot varieties, Hebei Province, "two diseases" 15 pilot varieties have been in the procurement of drug scope innovation, varieties through the consistent evaluation of drug production enterprises less than 3, allowing non-consistent evaluation enterprises to participate in bidding.It can be seen that the second round of volume procurement pilot varieties in self-funded drugs opened a mouth, the future will also have self-funded drugs into the volume of procurement pilot varieties, with volume procurement has become the official management of drug prices mechanism, whether in the national health insurance directory or outside the catalog, the relevant pharmaceutical companies should be prepared. (E drug manager)